Objective

To determine the current availability of care for headaches, in particular migraine in the Asian Oceanian region.

Method

A questionnaire-based, cross-sectional study from August 2020 to February 2021, surveyed country representatives from the member countries of the Asian Oceanian Association of Neurology. The items of the survey were influenced by the findings and recommendations of the 2011 Atlas of Headache by Lifting the Burden and the World Health Organization.

Results

Respondents from all of the 21 member countries of the Asian Oceanian Association of Neurology and 3 other Asian countries participated in this survey. All countries have an established neurological association except for Brunei where there are only 6 neurologists. Thirteen countries (54%) have a dedicated council for headaches. The majority have no subspecialty training program for headaches (75%). Prevalence studies are available in 14 countries while 10 out of the 24 have clinical practice guidelines. Among the 6 countries who offer subspecialty training for headache, only 3 countries cater foreign neurologists. Most of the countries have a wide selection of non-specific migraine drugs. All countries except for Mongolia have at least 1 triptan but non-oral forms for triptans are only available in 8 countries. Monoclonal antibody for migraine prophylaxis is available in 12 out of 24 countries (50%). The majority of respondents agree that migraine is under-diagnosed and under-treated by non-neurologists and that more time should be allotted for lectures dedicated to primary headaches in medical schools.

Conclusion

The survey showed the scarcity of clinical guidelines, subspecialty training, dedicated headache clinics, and patient advocacy organization for the care of headache patients in the participating countries. Acute and prophylactic medications approved for migraine are available in most countries but approved non-pharmacologic devices are lacking. The recommendations in the 2011 Atlas of Headache Disorders are still to be achieved.

中文翻译：

---

在亚洲大洋洲地区提供偏头痛护理：一项横断面研究

客观的

确定目前头痛护理的可用性，特别是亚洲大洋洲地区的偏头痛。

方法

从 2020 年 8 月到 2021 年 2 月，一项基于问卷的横断面研究对来自亚洲大洋洲神经病学协会成员国的国家代表进行了调查。调查项目受到 2011 年《减轻负担的头痛地图集》和世界卫生组织的调查结果和建议的影响。

结果

来自亚洲大洋洲神经病学协会所有 21 个成员国和其他 3 个亚洲国家的受访者参与了本次调查。除文莱只有 6 名神经科医生外，所有国家都建立了神经病学协会。13 个国家 (54%) 设有专门的头痛委员会。大多数人没有针对头痛的亚专业培训计划（75%）。14 个国家/地区提供流行率研究，而 24 个国家中有 10 个有临床实践指南。在提供头痛专科培训的 6 个国家中，只有 3 个国家为外国神经科医生提供服务。大多数国家都有多种非特异性偏头痛药物可供选择。除蒙古外，所有国家/地区至少有 1 种曲坦类药物，但曲坦类药物的非口服形式仅在 8 个国家/地区提供。用于预防偏头痛的单克隆抗体在 24 个国家中的 12 个 (50%) 可用。大多数受访者同意偏头痛被非神经科医生诊断不足和治疗不足，应为医学院的原发性头痛讲座分配更多时间。

结论

调查显示，参与国缺乏临床指南、专科培训、专门的头痛诊所和患者倡导组织来护理头痛患者。大多数国家都有批准用于偏头痛的急性和预防性药物，但缺乏批准的非药物设备。2011 年头痛疾病地图集中的建议仍有待实现。